NeuroBo Pharmaceuticals (NRBO) Short Interest Ratio & Short Volume → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free NRBO Stock Alerts $3.37 -0.07 (-2.03%) (As of 05:37 PM ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media NeuroBo Pharmaceuticals Short Interest DataCurrent Short Volume61,900 sharesPrevious Short Volume68,400 sharesChange Vs. Previous Month-9.50%Dollar Volume Sold Short$253,171.00Short Interest Ratio / Days to Cover0.0Last Record DateMarch 31, 2024Outstanding Shares4,910,000 sharesFloat Size3,200,000 sharesShort Percent of Float1.93%Today's Trading Volume20,562 sharesAverage Trading Volume1,106,447 sharesToday's Volume Vs. Average2% Short Selling NeuroBo Pharmaceuticals ? Sign up to receive the latest short interest report for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatNRBO Short Interest Over TimeNRBO Days to Cover Over TimeNRBO Percentage of Float Shorted Over Time Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story NeuroBo Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202461,900 shares $253,171.00 -9.5%1.9%0 $4.09 3/15/202468,400 shares $314,640.00 +67.2%2.2%0.1 $4.60 2/29/202440,900 shares $236,811.00 -68.9%1.3%0 $5.79 2/15/2024131,700 shares $636,111.00 +395.1%4.1%0.1 $4.83 1/31/202426,600 shares $86,982.00 +39.3%0.8%0 $3.27 1/15/202419,100 shares $64,558.00 +180.9%0.4%0.6 $3.38 Get the Latest News and Ratings for NRBO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 12/31/20236,800 shares $25,136.88 +15.3%0.2%0.2 $3.70 12/15/20235,900 shares $23,590.56 -90.1%0.2%0.5 $4.00 11/30/202359,600 shares $26,700.80 -31.8%N/A1 $0.45 11/15/202387,400 shares $37,599.48 -2.7%N/A1.3 $0.43 10/31/202389,800 shares $37,805.80 -29.5%N/A0.8 $0.42 10/15/2023127,400 shares $60,757.06 +4.3%N/A0.8 $0.48 9/30/2023122,200 shares $58,167.20 +11.1%N/A0.5 $0.48 9/15/2023110,000 shares $59,367.00 -20.1%N/A0.3 $0.54 8/31/2023137,700 shares $61,290.27 -48.0%0.8%0.4 $0.45 8/15/2023265,000 shares $163,770.00 +217.4%1.5%0.7 $0.62 7/31/202383,500 shares $42,835.50 -57.9%0.7%0.2 $0.51 7/15/2023198,500 shares $86,645.25 -67.5%1.5%0.5 $0.44 6/30/2023611,400 shares $267,242.94 +224.5%4.6%1.3 $0.44 6/15/2023188,400 shares $93,069.60 -20.6%1.4%0.5 $0.49 5/31/2023237,400 shares $132,944.00 -9.0%1.8%0.6 $0.56 5/15/2023261,000 shares $154,746.90 +15.6%2.0%0.5 $0.59 4/30/2023225,800 shares $144,512.00 +33.9%1.7%0.4 $0.64 4/15/2023168,600 shares $123,078.00 -26.5%2.3%0.2 $0.73 3/31/2023229,300 shares $162,871.79 -13.3%3.1%0.3 $0.71 3/15/2023264,500 shares $177,320.80 +28.1%4.2%0.2 $0.67 2/28/2023206,500 shares $132,160.00 -40.9%3.3%0.1 $0.64 2/15/2023349,400 shares $251,218.60 -46.1%5.6%0.1 $0.72 1/31/2023648,700 shares $512,473.00 +359.7%10.3%0.2 $0.79 1/15/2023141,100 shares $108,618.78 -85.3%2.2%0 $0.77 12/30/2022958,400 shares $687,652.00 -14.4%15.3%0.3 $0.72 12/15/20221,120,000 shares $1.69 million +29.4%N/A0.3 $1.51 11/30/2022865,400 shares $1.25 million -47.6%N/A0.3 $1.45 11/15/20221,650,000 shares $2.34 million +837.0%45.1%0.6 $1.42 10/31/2022176,100 shares $1.35 million +257.2%9.2%0.1 $7.68 10/15/202249,300 shares $628,575.00 -46.8%9.6%0.1 $12.75 9/30/202292,600 shares $1.27 million -12.3%17.9%0.2 $13.69 9/15/2022105,600 shares $2.62 million -34.5%24.7%0.2 $24.82 8/31/2022161,300 shares $51,422.44 -7.5%1.3%0.1 $0.32 8/15/2022174,400 shares $71,172.64 -5.4%1.4%2 $0.41Tiny Biotech Stock Wins $75 Billion Patent (Ad)A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>> NRBO Short Interest - Frequently Asked Questions What is NeuroBo Pharmaceuticals' current short interest? Short interest is the volume of NeuroBo Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 61,900 shares of NRBO short. 1.93% of NeuroBo Pharmaceuticals' shares are currently sold short. Learn More on NeuroBo Pharmaceuticals' current short interest. Which institutional investors are shorting NeuroBo Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of NeuroBo Pharmaceuticals: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for NeuroBo Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.93% of NeuroBo Pharmaceuticals' floating shares are currently sold short. Is NeuroBo Pharmaceuticals' short interest increasing or decreasing? NeuroBo Pharmaceuticals saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 61,900 shares, a drop of 9.5% from the previous total of 68,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is NeuroBo Pharmaceuticals' float size? NeuroBo Pharmaceuticals currently has issued a total of 4,910,000 shares. Some of NeuroBo Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. NeuroBo Pharmaceuticals currently has a public float of 3,200,000 shares. How does NeuroBo Pharmaceuticals' short interest compare to its competitors? 1.93% of NeuroBo Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to NeuroBo Pharmaceuticals: Avalo Therapeutics, Inc. (7.62%), Aytu BioPharma, Inc. (6.73%), Pieris Pharmaceuticals, Inc. (0.14%), Talphera, Inc. (0.70%), Orgenesis Inc. (0.87%), Minerva Neurosciences, Inc. (0.74%), Galecto, Inc. (0.16%), Cocrystal Pharma, Inc. (0.07%), VBI Vaccines Inc. (1.30%), Kiora Pharmaceuticals, Inc. (0.71%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short NeuroBo Pharmaceuticals stock? Short selling NRBO is an investing strategy that aims to generate trading profit from NeuroBo Pharmaceuticals as its price is falling. NRBO shares are trading down $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against NeuroBo Pharmaceuticals? A short squeeze for NeuroBo Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NRBO, which in turn drives the price of the stock up even further. How often is NeuroBo Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NRBO, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: AVTX Short Interest Data AYTU Short Interest Data PIRS Short Interest Data TLPH Short Interest Data ORGS Short Interest Data NERV Short Interest Data GLTO Short Interest Data COCP Short Interest Data VBIV Short Interest Data KPRX Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NRBO) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsBiden’s $374B Giveaway Into This SectorDTIHe Is Giving Away BitcoinCrypto Swap ProfitsSHOCKING Crypto Leak…Crypto 101 MediaThe #1 Crypto for 2024InvestorPlaceHow Biden has already won 2024Porter & CompanyUrgent alert: open this for a huge profit potentialTimothy SykesMy biggest AI fearParadigm Press